Insmed price target raised to $30 from $25 at H.C. Wainwright H.C. Wainwright raised its price target for Insmed shares to $30 following the company's Phase II data for Arikayce and keeps a Buy rating on the stock. The firm believes uncertainty over the drug's clinical meaningfulness has been removed with the data.
Insmed personnel strong, says Piper Jaffray After attending Insmed's analyst event, Piper says that the company has assembled a strong development and commercial team . The firm adds that the company has forged unique relationships with specialists and patients. It keeps an Overweight rating on the shares.